Lomecel-B Effects on Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Mild Alzheimer's Disease
Interventions
DRUG

Allogeneic MSC

An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation

OTHER

Placebo

Placebo

Trial Locations (13)

33125

Bruce W. Carter VA Medical Center, Miami

33137

Miami Jewish Health, Miami

33155

Allied Biomedical Research Institute, Miami

Ivetmar Medical Group, Miami

33157

Imic Inc., Palmetto Bay

33173

Fusion Medical Research and Clinic, Miami

33175

First Excellent Research Group, LLC, Miami

33176

Brainstorm Research, Miami

Miami Dade Medical Research Institute, Miami

33178

Science Connections - Research Partner Group Multispecialty Group, Doral

33180

Visionary Investigators Network, Aventura

33445

Brain Matters Research, Delray Beach

34997

Brain Matters Research, Stuart

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

bioRASI, LLC

INDUSTRY

lead

Longeveron Inc.

INDUSTRY

NCT05233774 - Lomecel-B Effects on Alzheimer's Disease | Biotech Hunter | Biotech Hunter